Cargando…

MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction

Background: Micro-RNA-21 (miR-21) is a post-translational regulator involved in epithelial-to-mesenchymal transition (EMT). Since EMT is thought to contribute to chronic lung allograft dysfunction (CLAD), we aimed to characterize miR-21 expression and distinct EMT markers in CLAD. Methods: Expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyahara, Naofumi, Benazzo, Alberto, Oberndorfer, Felicitas, Iwasaki, Akinori, Laszlo, Viktoria, Döme, Balasz, Hoda, Mir Ali, Jaksch, Peter, Klepetko, Walter, Hoetzenecker, Konrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842266/
https://www.ncbi.nlm.nih.gov/pubmed/35185369
http://dx.doi.org/10.3389/ti.2021.10184
_version_ 1784651013462949888
author Miyahara, Naofumi
Benazzo, Alberto
Oberndorfer, Felicitas
Iwasaki, Akinori
Laszlo, Viktoria
Döme, Balasz
Hoda, Mir Ali
Jaksch, Peter
Klepetko, Walter
Hoetzenecker, Konrad
author_facet Miyahara, Naofumi
Benazzo, Alberto
Oberndorfer, Felicitas
Iwasaki, Akinori
Laszlo, Viktoria
Döme, Balasz
Hoda, Mir Ali
Jaksch, Peter
Klepetko, Walter
Hoetzenecker, Konrad
author_sort Miyahara, Naofumi
collection PubMed
description Background: Micro-RNA-21 (miR-21) is a post-translational regulator involved in epithelial-to-mesenchymal transition (EMT). Since EMT is thought to contribute to chronic lung allograft dysfunction (CLAD), we aimed to characterize miR-21 expression and distinct EMT markers in CLAD. Methods: Expression of miR-21, vimentin, Notch intracellular domain (NICD) and SMAD 2/3 was investigated in explanted CLAD lungs of patients who underwent retransplantation. Circulating miR-21 was determined in collected serum samples of CLAD and matched stable recipients. Results: The frequency of miR-21 expression was higher in restrictive allograft syndrome (RAS) than in bronchiolitis obliterans syndrome (BOS) specimens (86 vs 30%, p = 0.01); Vimentin, NICD and p-SMAD 2/3 were positive in 17 (100%), 12 (71%), and 7 (42%) BOS patients and in 7 (100%), 4 (57%) and 4 (57%) RAS cases, respectively. All four markers were negative in control tissue from donor lungs. RAS patients showed a significant increase in serum concentration of miR-21 over time as compared to stable recipients (p = 0.040). Conclusion: To the best of our knowledge this is the first study highlighting the role miR-21 in CLAD. Further studies are necessary to investigate the involvement of miR-21 in the pathogenesis of CLAD and its potential as a therapeutic target.
format Online
Article
Text
id pubmed-8842266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88422662022-02-17 MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction Miyahara, Naofumi Benazzo, Alberto Oberndorfer, Felicitas Iwasaki, Akinori Laszlo, Viktoria Döme, Balasz Hoda, Mir Ali Jaksch, Peter Klepetko, Walter Hoetzenecker, Konrad Transpl Int Health Archive Background: Micro-RNA-21 (miR-21) is a post-translational regulator involved in epithelial-to-mesenchymal transition (EMT). Since EMT is thought to contribute to chronic lung allograft dysfunction (CLAD), we aimed to characterize miR-21 expression and distinct EMT markers in CLAD. Methods: Expression of miR-21, vimentin, Notch intracellular domain (NICD) and SMAD 2/3 was investigated in explanted CLAD lungs of patients who underwent retransplantation. Circulating miR-21 was determined in collected serum samples of CLAD and matched stable recipients. Results: The frequency of miR-21 expression was higher in restrictive allograft syndrome (RAS) than in bronchiolitis obliterans syndrome (BOS) specimens (86 vs 30%, p = 0.01); Vimentin, NICD and p-SMAD 2/3 were positive in 17 (100%), 12 (71%), and 7 (42%) BOS patients and in 7 (100%), 4 (57%) and 4 (57%) RAS cases, respectively. All four markers were negative in control tissue from donor lungs. RAS patients showed a significant increase in serum concentration of miR-21 over time as compared to stable recipients (p = 0.040). Conclusion: To the best of our knowledge this is the first study highlighting the role miR-21 in CLAD. Further studies are necessary to investigate the involvement of miR-21 in the pathogenesis of CLAD and its potential as a therapeutic target. Frontiers Media S.A. 2022-01-13 /pmc/articles/PMC8842266/ /pubmed/35185369 http://dx.doi.org/10.3389/ti.2021.10184 Text en Copyright © 2022 Miyahara, Benazzo, Oberndorfer, Iwasaki, Laszlo, Döme, Hoda, Jaksch, Klepetko and Hoetzenecker. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Miyahara, Naofumi
Benazzo, Alberto
Oberndorfer, Felicitas
Iwasaki, Akinori
Laszlo, Viktoria
Döme, Balasz
Hoda, Mir Ali
Jaksch, Peter
Klepetko, Walter
Hoetzenecker, Konrad
MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction
title MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction
title_full MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction
title_fullStr MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction
title_full_unstemmed MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction
title_short MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction
title_sort mir-21 in lung transplant recipients with chronic lung allograft dysfunction
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842266/
https://www.ncbi.nlm.nih.gov/pubmed/35185369
http://dx.doi.org/10.3389/ti.2021.10184
work_keys_str_mv AT miyaharanaofumi mir21inlungtransplantrecipientswithchroniclungallograftdysfunction
AT benazzoalberto mir21inlungtransplantrecipientswithchroniclungallograftdysfunction
AT oberndorferfelicitas mir21inlungtransplantrecipientswithchroniclungallograftdysfunction
AT iwasakiakinori mir21inlungtransplantrecipientswithchroniclungallograftdysfunction
AT laszloviktoria mir21inlungtransplantrecipientswithchroniclungallograftdysfunction
AT domebalasz mir21inlungtransplantrecipientswithchroniclungallograftdysfunction
AT hodamirali mir21inlungtransplantrecipientswithchroniclungallograftdysfunction
AT jakschpeter mir21inlungtransplantrecipientswithchroniclungallograftdysfunction
AT klepetkowalter mir21inlungtransplantrecipientswithchroniclungallograftdysfunction
AT hoetzeneckerkonrad mir21inlungtransplantrecipientswithchroniclungallograftdysfunction